Table 1.
Baseline and sample characteristics in lung transplant recipients with and without RVI.
| Characteristics | Cases, n = 21 | Controls, n = 21 |
|---|---|---|
| Age in years, median (IQR) | 56 (51–64) | 58 (45–63) |
| Female sex, n (%) | 8 (38.1) | 8 (38.1) |
| Underlying pulmonary disease, n (%) | ||
| COPD/Bronchiectasis | 8 (38.1) | 6 (28.6) |
| IPF | 6 (28.6) | 6 (28.6) |
| Cystic Fibrosis | 2 (9.5) | 5 (23.8) |
| Other | 5 (23.8) a | 4 (19.0) b |
| Single lung transplant, n (%) | 4 (19.0) | 2 (9.5) |
| Year of transplant | ||
| 2007–2009 | 14 (66.7) | 13 (61.9) |
| 2010–2011 | 7 (33.3) | 8 (38.1) |
| Days, transplant to first serum sample, median (IQR) | 19 (15–23) | 17 (13–21) |
| Days, transplant to second serum sample, median (IQR) | 179 (154–225) | 180 (154–225) |
COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary fibrosis; a Alpha-1 antitrypsin (1), sarcoidosis (1), interstitial lung disease (3); b Alpha-1-antitrypsin (1), LAM (1), pulmonary hypertension (1), interstitial lung disease (1).